Literature DB >> 19550129

Application of multislice spiral CT angiography on transcatheter arterial chemoembolization for hepatocellular carcinoma.

Jin-Hua Huang1, Wei-Jun Fan, Chang-Jiang Li, Yang-Kui Gu, Liang Zhang, Fei Gao, Lian-Wei Lu, Wen-Quan Li.   

Abstract

BACKGROUND AND
OBJECTIVE: Multislice spiral CT angiography (MSCTA) is very important in the diagnosis and treatment of liver diseases. Currently, most studies on three-dimensional MSCTA of the liver vascular system focus on the liver tumors, preoperative assessment of liver transplantation and the systematic anatomy of the liver vascular system. This study was to investigate the clinical application of MSCTA on transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) by comparing images of MSCTA and digital subtraction angiography (DSA).
METHODS: MSCT dual-phase enhanced scanning was performed in 50 patients with advanced HCC. Both hepatic artery angiography and portal vein angiography were conducted using maximal intensity projection (MIP) and volume rendering technique (VRT). DSA of the celiac artery, superior mesenteric artery, renal artery and diaphragm artery, as well as TACE were performed in all patients. MSCTA and DSA images of the 50 patients were compared.
RESULTS: MSCTA and DSA showed equal detectability in revealing classification of the hepatic artery anatomy and tumor blood vessels, with a coincidence of 100% (p = 1.00). However, MSCTA was superior to DSA in displaying arterioportal shunt and portal vein tumor thrombus.
CONCLUSIONS: As a noninvasive and easy to conduct technique, MSCTA can accurately provide information of the hepatic artery, portal vein and tumor supply vessels. Therefore MSCTA has a favorable value to guide TACE for HCC.

Entities:  

Mesh:

Year:  2009        PMID: 19550129

Source DB:  PubMed          Journal:  Ai Zheng


  1 in total

1.  Tumor feeding artery reconstruction with multislice spiral CT in the diagnosis of pelvic tumors of unknown origin.

Authors:  Hai-Jing Hu; Yong-Wen Huang; Ying-Chang Zhu
Journal:  Diagn Interv Radiol       Date:  2014 Jan-Feb       Impact factor: 2.630

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.